- ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size is expected to reach US$9.26 billion by 2030.3
- There is strong evidence for use of NSAIDs as first-line treatment for migraine, and celecoxib is in same class of agents, fast acting and has the potential to have the lowest GI side effects of all NSAIDs.2
- ELYXYBTM has the potential to further expand Scilex’s non-opioid portfolio in broader acute pain indications and its acquisition establishes a growth platform for Scilex and fits within Scilex’s existing commercial team.
- The pain management therapeutics market size is estimated to reach US$ 101.27 billion by 2029 and growing at a CAGR of 4.3% from 2022 to 2030.4
- ELYXYBTM is protected by six Orange Book-listed method-of-use patents that expire in 2036.
- Scilex is well-positioned to market and distribute ELYXYBTM:
- Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.
- Scilex has a very experienced commercial and managed care team that has successfully launched and grown market access for ZTlido (lidocaine topical system) for over 200 million covered lives in the U.S.
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Feb 13, 2023
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers